Equity awards for Metagenomi Therapeutics (MGX) officer Matthew Wein
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Wein Matthew reported acquisition or exercise transactions in this Form 4 filing.
Metagenomi Therapeutics officer Matthew Wein received new equity awards. On April 1, 2026, he was granted options to buy 68,000 shares of common stock at $1.34 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, with the rest in 36 equal monthly installments, contingent on continued service. He was also granted 11,000 restricted stock units that begin vesting 25% on June 5, 2027, then in 12 equal quarterly installments. Following these compensation-related grants, his direct common stock holdings total 125,549 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Wein Matthew
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 68,000 | $0.00 | -- |
| Grant/Award | Common Stock | 11,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 68,000 shares (Direct);
Common Stock — 125,549 shares (Direct)
Footnotes (1)
- These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Key Figures
Stock options granted: 68,000 shares
Option exercise price: $1.34 per share
Option expiration date: March 31, 2036
+5 more
8 metrics
Stock options granted
68,000 shares
Option grant on April 1, 2026
Option exercise price
$1.34 per share
Stock Option (Right to Buy) on common stock
Option expiration date
March 31, 2036
End of option term for 68,000-share grant
RSUs granted
11,000 units
Common stock RSU award on April 1, 2026
RSU initial vesting
25% on June 5, 2027
First vesting tranche for 11,000 RSUs
RSU remaining vesting
12 equal quarterly installments
Remaining RSU vesting after June 5, 2027
Post-grant common shares held
125,549 shares
Direct common stock holdings after April 1, 2026 grant
Option vesting schedule
25% on April 1, 2027; rest over 36 months
Vesting pattern for 68,000-share option grant
Key Terms
restricted stock units ("RSUs"), vest, stock option, quarterly installments, +1 more
5 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027,"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vest financial
"25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
stock option financial
"25% of the shares subject to this option shall vest and become exercisable on April 1, 2027,"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
quarterly installments financial
"with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service"
monthly installments financial
"with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service"
Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.
FAQ
What insider equity awards did Metagenomi Therapeutics (MGX) grant to Matthew Wein?
Metagenomi Therapeutics granted Matthew Wein new stock options and restricted stock units as compensation. He received options for 68,000 common shares at $1.34 per share and 11,000 RSUs, both subject to multi-year vesting schedules tied to his continued service with the company.
How many Metagenomi Therapeutics (MGX) stock options did Matthew Wein receive and at what price?
Matthew Wein received stock options for 68,000 shares of Metagenomi Therapeutics common stock at an exercise price of $1.34 per share. These options vest over four years and expire on March 31, 2036, aligning his potential upside with the company’s long-term performance and retention.
What are the vesting terms for Matthew Wein’s Metagenomi (MGX) restricted stock units?
Wein’s 11,000 restricted stock units vest over several years based on continued service. 25% of the RSUs vest on June 5, 2027, with the remaining units vesting in 12 equal quarterly installments thereafter, gradually converting into common shares as conditions are met.
Are Matthew Wein’s Metagenomi (MGX) Form 4 transactions open-market purchases or compensation grants?
The reported transactions are compensation-related grants, not open-market purchases or sales. Both the 68,000 stock options and 11,000 RSUs were awarded at a per-share price of $0.00, with vesting schedules that depend on Wein’s continued service with Metagenomi Therapeutics.